Translational research in cutaneous melanoma: New therapeutic perspectives

Antonio Marra, Cristina R. Ferrone, Celeste Fusciello, Giosuè Scognamiglio, Soldano Ferrone, Stefano Pepe, Francesco Perri, Francesco Sabbatino

Research output: Contribution to journalReview articlepeer-review


Melanoma is an aggressive form of skin cancer characterized by poor prognosis and high mortality. The development of targeted agents based on the discovery of driver mutations as well as the implementation of checkpoint inhibitor-based immunotherapy represents a major breakthrough in the treatment of metastatic melanoma. However, in both cases the development of drug resistance and immune escape mechanisms as well as the lack of predictive biomarkers limits their extraordinary clinical efficacy. In this article, we summarize the available therapeutic options for patients with metastatic melanoma, outline the mechanisms implicated in the resistance to both targeted agents and immunotherapy, discuss potential predictive biomarkers and outline future therapeutic approaches under investigation.

Original languageEnglish
Pages (from-to)166-181
Number of pages16
JournalAnti-Cancer Agents in Medicinal Chemistry
Issue number2
Publication statusPublished - Jan 1 2018


  • BRAF inhibitor resistance
  • Immune checkpoint molecules
  • Immunotherapy
  • Immunotherapy resistance
  • Melanoma
  • PD-1
  • PD-L1
  • Predictive biomarkers
  • Targeted therapy

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology
  • Cancer Research


Dive into the research topics of 'Translational research in cutaneous melanoma: New therapeutic perspectives'. Together they form a unique fingerprint.

Cite this